UNSPSC 51401570: Midazolam maleate

This classification denotes a benzodiazepine with the molecular formula C18H13ClFN3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 77520S18SE, chemically known as 8-chloro-6-(o-fluorophenyl)-1-methyl-4h-imidazo(1,5-a)(1,4)benzodiazepine maleate (1:1) but more generally known as midazolam maleate, which bears US NIH Compound Identifier 5384200. European Medicines Agency schedules Midazolam maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14573MIG.

Most nations, for tariff and trade purposes, schedule midazolam maleate under HS 29339100 and SITC 51577. As of Q4 2014, MIDAZOLAM MALEATE remains US FDA's Preferred Term for this commodity. SMILES: CC1NCC2N1-C3CCC(CC3C(=NC2)C4CCCCC4F)CL.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51401570 Midazolam maleate is a Commodity code that represents pharmaceutical products, though recent state and local procurement activity under this code shows minimal direct solicitation for midazolam specifically. Instead, issuing bodies are purchasing pharmaceuticals through broader multi-source generic drug procurement vehicles and specialized health initiatives focused on opioid-related medications and overdose interventions. The scope of work encompasses supply of FDA-compliant pharmaceutical products meeting current Good Manufacturing Practices and Drug Supply Chain Security Act certification, with vendors required to maintain established relationships with authorized wholesalers, manage complex pricing structures (fixed price, net price formats, or WAC-minus models), and provide detailed product information including National Drug Codes, SKUs, and expiration-date certifications with minimum shelf-life guarantees.

Issuing bodies soliciting under this code span state health and human services departments, county health systems, and multistate cooperative purchasing alliances. The Texas Health and Human Services Commission, Minnesota Department of Administration (administering MMCAP), and Seminole County, Florida represent the geographic and organizational spread in recent activity. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026 and requiring contracts with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, or Morris & Dickson). Seminole County, Florida posted IFB 60459723LAS in June 2026 for 1,900 annual units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the county community health building, due July 26, 2023. The Texas HHS Commission issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling exploration of alternative pharmacy distribution models ahead of formal procurement.